Overview

• U.S. biopharma firm's Q1 net loss narrowed from prior year on lower operating expenses

• Company dosed first participant in FORTIFY Phase 1b trial of PLN-101095 in April

• Updated Phase 1 data for PLN-101095 showed deepening responses in checkpoint inhibitor-refractory tumors

Outlook

• Company expects interim data from FORTIFY Phase 1b trial in 2027

• Pliant expects cash resources to fund operations into second half of 2028

• Company continues preclinical studies for integrin-targeted drug delivery platform

Result Drivers

• CLINICAL TRIAL PROGRESS - Co initiated FORTIFY Phase 1b trial of PLN-101095 ahead of schedule and dosed first participant in April

• UPDATED PHASE 1 DATA - Updated Phase 1 trial data for PLN-101095 showed deepening of confirmed responses in checkpoint inhibitor-refractory solid tumors

• LOWER OPERATING EXPENSES - Net loss narrowed mainly due to lower research and development and general administrative expenses after completion of prior clinical program and reduced headcount

Company press release: ID:nGNX7w8JJv

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q1 EPS		-$0.32

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 4 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the pharmaceuticals peer group is "buy"

• Wall Street's median 12-month price target for Pliant Therapeutics Inc is $3.00, about 145.9% above its May 8 closing price of $1.22

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.